Core Viewpoint - 九州通's subsidiary received approval for the listing application of Betahistine Dihydrochloride Tablets, which are used for Meniere's disease and cerebral vascular diseases, indicating potential growth in product offerings to meet aging population needs [1] Recent Events - 九州通 announced that its controlling shareholder, Chuchang Investment, has prematurely released the pledge of 11.3 million shares (2.46% of its holdings), while a related party, Shanghai Hongkang, pledged 11.7 million shares (1.08% of its holdings). As of the announcement date, the total pledged shares by Chuchang Investment accounted for 57.29% of its holdings and 26.03% of the company's total share capital [2] - The company is positioned as a digital service provider in the AI medical ecosystem, supporting the Ant Group's supply chain, with over 50 million orders in 2025, reflecting a 180% year-on-year increase [2] Stock Performance - As of February 12, 2026, 九州通's stock price was 5.21 yuan, with a cumulative decline of 1.14% over the past five days and a price fluctuation of 2.66%. The net outflow of main funds was 11.51 million yuan, with a turnover rate of 0.23%. The technical analysis indicates the stock is in a consolidation phase, with a 20-day moving average of 5.31 yuan, a Bollinger Band resistance level of 5.56 yuan, and a support level of 5.08 yuan [3] Institutional Viewpoints - The market is focusing on the integration of AI medical technology and pharmaceutical distribution digitalization. 九州通 is enhancing supply chain efficiency through smart warehousing and blockchain technology, with its pharmaceutical industrial business generating 2.3 billion yuan in revenue in the first three quarters of 2025, a year-on-year increase of 9.93%. However, there is uncertainty regarding the approval results for the newly accepted drugs [4]

Core Viewpoint - The company, known for transforming traditional pharmaceutical distribution through the internet, has seen its stock price plummet below its initial offering price despite revenue and profit growth, indicating a fundamental failure in its business model [1][6]. Business Model Transformation - Founded in 2015, the company aimed to create a digital platform connecting drug suppliers with pharmacies to address information asymmetry and channel chaos in the outpatient pharmaceutical market [7]. - The traditional pharmaceutical distribution model is linear, leading to high end-user prices due to markups at each stage [8]. - The company proposed a "flattening" of this process, allowing pharmacies to connect directly with suppliers through its platform, embodying typical internet platform thinking [9]. - However, increased competition and capital pressure led to a shift towards a "platform + self-operated" dual model, where self-operated business began to dominate, accounting for 94.67% of operations by mid-2024 [10]. - The self-operated business model relies on using supplier data to produce competing products, undermining trust in the platform [11]. Stock Price Decline - The stock price has dramatically fallen from a peak of 64.5 HKD in August 2023 to 5.62 HKD, resulting in a market value loss of over 30 billion HKD [12]. - The decline began on December 13, 2023, coinciding with the lifting of a lock-up period for pre-IPO shareholders, leading to a 46% drop in a single day [13]. - This capital exodus reflects a complete loss of confidence in the company's business model, exacerbated by new regulatory requirements [13][15]. Strategic Positioning - The company positions itself as a "digital comprehensive service platform for the outpatient pharmaceutical industry," but fundamentally remains a traditional pharmaceutical distributor [18]. - Unlike competitors like JD Health and Alibaba Health, which leverage real supply chain capabilities, the company struggles with logistics and lacks direct cooperation with pharmaceutical companies [20]. - The company's strategic direction has been inconsistent, attempting to expand into various areas, which has diluted focus and resources [22]. Financial Performance - Financially, the company appears to be improving, with a net profit of 150.81 million in 2024 and 78.117 million in the first half of 2025 [23]. - However, the growth is based on a fragile foundation, with self-operated business gross margins at only 5.9%, while platform business margins are significantly higher at 84.2% [24]. - The reliance on high sales volume for profitability is concerning, with a net profit margin of only 0.08% in 2024 [25]. - Cash flow remains under pressure despite reported profits, raising concerns about sustainability [26]. Industry Insights - The case of the company highlights the importance of compliance in the pharmaceutical industry, emphasizing that digitalization must not bypass essential regulations [29]. - The industry must focus on building compliant supply chains and enhancing efficiency rather than attempting to circumvent regulations [30]. - Future competition in the pharmaceutical e-commerce sector will hinge on supply chain stability, service professionalism, and data authenticity, rather than mere price competition [33].